FDA's Module 1 Update: From Ideas to Implementation

Jared C. Lantzy, PMP
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.

These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.
Agenda

- Why? – Advantages to FDA
- What? – Significant changes
- Who? – Impact to stakeholders
- When? – Implementation timeline
- Where? – Getting help
- Questions I can answer
- Questions I can’t answer

© 2015 DIA, Inc. All rights reserved.
Advantages to FDA

- Automation
  - 46,494 Form FDA 2253 submissions to CDER OPDP in CY2014 (roughly 80,000 materials)

- Grouped submissions
  - Using grouped submissions is optional!

- Maintainability
  - Attribute code lists

- Keeping up with business
  - CTOC updates
  - Submission metadata

© 2015 DIA, Inc. All rights reserved.
Significant changes

- **id**
  - D-U-N-S number of your corporate HQ

- **submission-description (optional)**
  - A high level description of the purpose of the submission

- **applicant-contacts**

- The cross-reference-application-number electronically provides the same information found on the 356h form
  - CROSS REFERENCES (List related License Applications, INDs, NDAs, PMAs, 510(k), IDF, BMFs, and DMFs referenced in the current application.)
  - A cross reference only needs to be identified once
  - Does not replace the information submitted in m1.4.4
Significant changes (2)

- Removed elements
- Building regulatory activities
  - Submission-id and sequence number
- Application forms
  - What is considered an application form?
Removed elements

- **Date of submission (date format)**
  - Dates were often wrong – sometimes off by a day; sometimes off by years
  - FDA review tools will display the “receipt date” from our regulatory tracking system

- **Product information (type and name)**
  - Multiple errors for missing product information or information that has changed

- **Related sequence number**
  - Errors for multiple related sequence numbers or circular references
  - This concept is simplified by using submission-id and sequence-number in the new M1
Building regulatory activities

- **Regulatory Activity** = The entire group of submissions supporting a specific regulatory activity
  - e.g., an original application and all its amendments leading to approval
- **Within each application:**
  - submission-id = first sequence number for each “new” regulatory activity (change in submission-type)
  - e.g., a new efficacy supplement to an approved application is a new regulatory activity
  - Submission-id remains constant (the same) to group submissions together into their specific regulatory activity
- **Sequence-number = concept is unchanged**
  - Must be unique within the application
  - 4 digits
  - Start at 0001, even for presubmissions

© 2015 DIA, Inc. All rights reserved.
Application forms

1571, 356h, 2252, and 2253
- A single form per application

Grouped submissions require 1 form per application referenced in the admin section of the us-regional
- Exceptions:
  - grouped submissions to the same application – see addendum 2 on M1 website
  - grouped promotional labeling and advertising submissions

Promotional labeling and advertising submissions do not require a 356h
Impact to stakeholders

Industry

• Opportunity for companies to develop streamlined processes to submit high volume 2253s electronically over the electronic submission gateway (ESG)

• Challenge of maintaining unique sequence numbers if 3rd parties are involved in preparation or submission

• Opportunity to send a single grouped submission that previously required many sequences

• Challenge of identifying grouped submissions where all content is truly shared in the same eCTD heading location
Impact to stakeholders (2)

- FDA
  - Major updates to validation, processing, and tracking systems
  - Learning curve with updated review software
  - Electronic submission volume continues to increase
Implementation timeline

▶ Past
  • Testing… testing… 1… 2… 3(years?)…

▶ Thank you for your help in the recent pilot!
  • 7 individual sponsors/vendors and approximately 50+ sequences submitted
  • Results were sent to individuals, were used to create this presentation, and will inform future updates to specifications

© 2015 DIA, Inc. All rights reserved.
Implementation timeline (2)

- **Present**
  - Final tweaks to systems
  - Reviewer training

- **Outreach**
  - DIA
  - Webinars
Implementation timeline (3)

Future

• 30 days notice before the public acceptance date
• Expected in the 3rd Quarter of FY 2015 (which ends June 30, 2015)
• Transition to the new M1
• Maintenance of specifications and code lists
• The retirement date for us-regional DTD v2.01 has not been set
Using the new M1 is optional
• If you do not need to submit promotional materials

Using the new M1 will be necessary to submit:
• Promotional labeling and advertising submissions to CDER OPDP
• Grouped submissions

After transitioning an application to the new M1, that application must continue to use the new M1
• Do not mix DTD v3.3 and older DTD version submissions
Getting help

- esub@fda.hhs.gov
  - Yes, you can cc me

- CDER eCTD Web page
  - Guidances, specifications, and supporting files
  - Includes the new M1 documents

- CDER Electronic Submissions Presentations Web page
  - Archive of presentations including general eCTD topics
Questions I can answer

CDER OPDP submissions

• Do not submit a 356h form with promotional labeling and advertising submissions
• Do not submit a cover letter in section 1.2; promotional labeling and advertising correspondence belongs in 1.15.1
  • No correspondence for 2253 submissions
• Form 2253 should be included with draft submissions to CBER APLB, but not to CDER OPDP
• Use life cycle if you are withdrawing materials or fixing a mistake in a previous submission
• Reference all product labeling in 1.14.6 for grouped submissions
Grouped Submissions

- Rejection for any reason will lead to rejection for all applications in the group
- Submission can be “un-grouped” at any time by submitting new/changed files to a single application only
- FDA review tools will be modified to show some grouped submission information for support and review purposes
- Only 1 form is needed when submitting to multiple regulatory activities in a single application (see errata 2)
M1 New Specifications

- The id element should be completed with your corporate HQ D-U-N-S #
  - Pick the corporate HQ of the sponsor/applicant if more than 1 party is submitting
  - Each establishment reported on the 356h also needs a D-U-N-S
- A technical contact should be prepared to discuss eCTD publishing and processing issues
- Only 1571 forms and 356h forms belong in the admin section of the us-regional (this is for your tool vendors)
Questions I can’t answer

How do we manage eCTD sequence numbers if a 3rd party will be preparing promotional labeling and advertising submissions?

• Sorry, we can’t tell you HOW to manage them. You will need to manage them as duplicate sequence numbers will be rejected.

How do I submit xyz promotional material?

• Start with the guidance
  • Draft Guidance for Industry: Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs
Questions I can’t answer (2)

► When will us-regional DTD v3.3 be required?
  • It will be, if you need to submit 2253 submissions

► How do I complete FDA Form XYZ?
  • There is a list of contact POCs next to each form on the [FDA Forms Web page](#)
Thank you!

Jared C. Lantzy, PMP
Operations Research Analyst
Office of Business Informatics (OBI), OSP, CDER
FDA, United States
(301)796-0597
jared.lantzy@fda.hhs.gov
esub@fda.hhs.gov
Ask